Cipher Pharmaceuticals Inc. (CPH.TO)
CAD 14.56
(3.41%)
CAD 14.56
(3.41%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 11.26 Million USD | -13.19% |
| 2022 | 11.95 Million USD | -3.58% |
| 2021 | 13.65 Million USD | -6.56% |
| 2020 | 13.4 Million USD | 4.14% |
| 2019 | 12.86 Million USD | 108.96% |
| 2018 | 6.15 Million USD | -76.51% |
| 2017 | 26.03 Million USD | 502.94% |
| 2016 | 12.66 Million USD | -8.81% |
| 2015 | 7.19 Million USD | 235.19% |
| 2014 | 17.7 Million USD | -119.48% |
| 2013 | 18.1 Million USD | 424.62% |
| 2012 | 3.45 Million USD | 297.44% |
| 2011 | -1.74 Million USD | -334.08% |
| 2010 | 862.86 Thousand USD | 138.54% |
| 2009 | -1.93 Million USD | 29.08% |
| 2008 | -2.73 Million USD | 59.87% |
| 2007 | -6.8 Million USD | 31.44% |
| 2006 | -9.92 Million USD | 29.99% |
| 2005 | -14.18 Million USD | -172.68% |
| 2004 | -5.2 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 3.98 Million USD | 30.98% |
| 2024 Q2 | 3.56 Million USD | -13.85% |
| 2023 Q2 | 2.18 Million USD | -18.38% |
| 2023 Q4 | 1.88 Million USD | -49.41% |
| 2023 Q1 | 2.68 Million USD | -4.86% |
| 2023 FY | - USD | -13.19% |
| 2023 Q3 | 3.72 Million USD | 70.21% |
| 2022 Q2 | 3.55 Million USD | 16.24% |
| 2022 Q4 | 2.81 Million USD | 7.64% |
| 2022 FY | - USD | -3.58% |
| 2022 Q1 | 3.06 Million USD | -24.44% |
| 2022 Q3 | 2.61 Million USD | -26.39% |
| 2021 Q4 | 4.05 Million USD | 85.66% |
| 2021 Q1 | 2.27 Million USD | -39.21% |
| 2021 Q2 | 4.01 Million USD | 76.69% |
| 2021 Q3 | 2.18 Million USD | -45.69% |
| 2021 FY | - USD | -6.56% |
| 2020 FY | - USD | 4.14% |
| 2020 Q1 | 3.92 Million USD | -2.54% |
| 2020 Q2 | 2.95 Million USD | -24.69% |
| 2020 Q3 | 2.79 Million USD | -5.52% |
| 2020 Q4 | 3.74 Million USD | 34.09% |
| 2019 Q2 | 3.1 Million USD | 67.67% |
| 2019 Q4 | 4.02 Million USD | 3.55% |
| 2019 Q3 | 3.88 Million USD | 25.04% |
| 2019 FY | - USD | 108.96% |
| 2019 Q1 | 1.85 Million USD | 107.74% |
| 2018 Q2 | 3.07 Million USD | 241.02% |
| 2018 FY | - USD | -76.51% |
| 2018 Q4 | 892 Thousand USD | -30.75% |
| 2018 Q3 | 1.28 Million USD | -58.13% |
| 2018 Q1 | 902 Thousand USD | -88.83% |
| 2017 Q3 | 6.58 Million USD | 0.69% |
| 2017 Q1 | 5.02 Million USD | -70.27% |
| 2017 FY | - USD | 502.94% |
| 2017 Q4 | 8.07 Million USD | 22.67% |
| 2017 Q2 | 6.53 Million USD | 29.95% |
| 2016 Q3 | 1.48 Million USD | -22.0% |
| 2016 FY | - USD | -8.81% |
| 2016 Q2 | 1.9 Million USD | 501.27% |
| 2016 Q1 | 316 Thousand USD | 74.59% |
| 2016 Q4 | 16.91 Million USD | 1041.43% |
| 2015 Q3 | -734 Thousand USD | -145.58% |
| 2015 FY | - USD | 235.19% |
| 2015 Q4 | 181 Thousand USD | 124.66% |
| 2015 Q2 | 1.61 Million USD | -54.03% |
| 2015 Q1 | 3.5 Million USD | -0.94% |
| 2014 Q4 | 3.53 Million USD | -15.9% |
| 2014 FY | - USD | -119.48% |
| 2014 Q1 | 4.62 Million USD | -52.68% |
| 2014 Q2 | 5.63 Million USD | 21.63% |
| 2014 Q3 | 4.2 Million USD | -25.32% |
| 2013 Q4 | 9.78 Million USD | 181.98% |
| 2013 Q2 | 3.11 Million USD | 83.66% |
| 2013 Q1 | 1.69 Million USD | 1.1% |
| 2013 FY | - USD | 424.62% |
| 2013 Q3 | 3.46 Million USD | 11.22% |
| 2012 Q4 | 1.67 Million USD | 67.53% |
| 2012 FY | - USD | 297.44% |
| 2012 Q1 | 331.75 Thousand USD | 210.98% |
| 2012 Q2 | 418.83 Thousand USD | 26.25% |
| 2012 Q3 | 1 Million USD | 139.42% |
| 2011 Q2 | -475.72 Thousand USD | 55.37% |
| 2011 FY | - USD | -334.08% |
| 2011 Q1 | -1.06 Million USD | -504.9% |
| 2011 Q4 | -298.92 Thousand USD | -4331.38% |
| 2011 Q3 | -6745.69 USD | 98.58% |
| 2010 FY | - USD | 138.54% |
| 2010 Q3 | -83.31 Thousand USD | -109.54% |
| 2010 Q2 | 873.73 Thousand USD | 371.55% |
| 2010 Q1 | -321.75 Thousand USD | 33.12% |
| 2010 Q4 | 263.25 Thousand USD | 415.99% |
| 2009 Q4 | -481.09 Thousand USD | -69.06% |
| 2009 FY | - USD | 29.08% |
| 2009 Q1 | -487.84 Thousand USD | -1216.39% |
| 2009 Q2 | -505.89 Thousand USD | -3.7% |
| 2009 Q3 | -284.56 Thousand USD | 43.75% |
| 2008 Q4 | -37.05 Thousand USD | -401.79% |
| 2008 FY | - USD | 59.87% |
| 2008 Q3 | 12.28 Thousand USD | 100.7% |
| 2008 Q2 | -1.74 Million USD | -66.11% |
| 2008 Q1 | -1.05 Million USD | 37.88% |
| 2007 Q4 | -1.69 Million USD | -44.19% |
| 2007 Q3 | -1.17 Million USD | 40.98% |
| 2007 FY | - USD | 31.44% |
| 2007 Q1 | -1.52 Million USD | -418.96% |
| 2007 Q2 | -1.99 Million USD | -30.5% |
| 2006 Q4 | -294.14 Thousand USD | 85.51% |
| 2006 Q2 | -4.62 Million USD | -61.23% |
| 2006 Q3 | -2.03 Million USD | 56.07% |
| 2006 FY | - USD | 29.99% |
| 2006 Q1 | -2.86 Million USD | 23.83% |
| 2005 Q2 | -4.43 Million USD | -105.01% |
| 2005 Q3 | -3.5 Million USD | 21.0% |
| 2005 Q4 | -3.76 Million USD | -7.5% |
| 2005 FY | - USD | -172.68% |
| 2005 Q1 | -2.16 Million USD | 0.0% |
| 2004 Q2 | -3.79 Million USD | -217.14% |
| 2004 Q1 | -1.19 Million USD | 0.0% |
| 2004 Q3 | 15.59 Million USD | 511.3% |
| 2004 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aurora Cannabis Inc. | 20.47 Million CAD | 45.003% |
| Avicanna Inc. | -7.35 Million CAD | 253.084% |
| Avant Brands Inc. | 4.83 Million CAD | -132.837% |
| Cardiol Therapeutics Inc. | -27.87 Million CAD | 140.387% |
| Crescita Therapeutics Inc. | 45 Thousand CAD | -24922.222% |
| Knight Therapeutics Inc. | 40.89 Million CAD | 72.467% |
| MediPharm Labs Corp. | -10.47 Million CAD | 207.463% |
| OrganiGram Holdings Inc. | -207.61 Million CAD | 105.423% |
| Canopy Growth Corporation | -312.82 Million CAD | 103.599% |
| Willow Biosciences Inc. | -11.06 Million CAD | 201.799% |
| Auxly Cannabis Group Inc. | -10.82 Million CAD | 204.018% |